Cimzia (certolizumab)

TNFI bilogic drug used for autoimmune disease including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. 

Inhibits TNF-alpha

CIMZIA is administered by subcutaneous injection

Crohn’s Disease

• 400 mg initially and at Weeks 2 and 4. If response occurs, follow with

400 mg every four weeks

Rheumatoid Arthritis 

• 400 mg initially and at Weeks 2 and 4, followed by 200 mg every other

week; for maintenance dosing, 400 mg every 4 weeks can be considered

Polyarticular Juvenile Idiopathic Arthritis 

• 10 kg (22 lbs) to less than 20 kg (44 lbs): 100 mg initially and at Weeks

2 and 4, followed by 50 mg every other week

• 20 kg (44 lbs) to less than 40 kg (88 lbs): 200 mg initially and at Weeks

2 and 4, followed by 100 mg every other week

• Greater than or equal to 40 kg (88 lbs): 400 mg initially and at Weeks 2

and 4, followed by 200 mg every other week

Psoriatic Arthritis 

• 400 mg initially and at week 2 and 4, followed by 200 mg every other

week; for maintenance dosing, 400 mg every 4 weeks can be considered.

Ankylosing Spondylitis 

• 400 mg (given as 2 subcutaneous injections of 200 mg each) initially

and at weeks 2 and 4, followed by 200 mg every other week or 400 mg

every 4 weeks.